Therapeutic advancements in juvenile idiopathic arthritis

Juvenile idiopathic arthritis in multiplex families: longitudinal follow-up

“…Advances in JIA management and better disease control with the growing number of effective medications including biologic agents have improved the survival and outcomes of children with JIA . Accordingly, predictors of long‐term outcomes and outcome assessment comprising social, educational and employment issues have been an attractive research consideration …”

Treatment in juvenile rheumatoid arthritis and new treatment options

“…It is not recommended to be used in systemic JIA, since the risk of side effects is increased. The initial dose is 10-20 mg/kg/day and the dose is increased to 30-50 mg/kg/day in weeks (1)(2)(3)(11)(12)(13)(14).…”

“…Therefore, side effects should be monitored by repeating liver enzymes and complete blood count every 2-3 months. Addition of 1mg/kg/day folinic acid or folic acid is recommended to decrease the effects on the bone marrow and control the side effects including nausea, oral ulcers and moderate hair loss (12). However, it should be kept in mind that folic acid may decrease the effect of methotrexate.…”

“…In addition, the patient's preference should be considered in terms of the mode of administration and frequency of administration. The limitations for use of these drugs include inadequate long-term safety data and cost, though they are efficient drugs (1)(2)(3)(11)(12)(13)(14).…”

Ultrasound in juvenile idiopathic arthritis

“…In the recent years, the availability of powerful and expensive drugs increased the need to identify patients with a high likelihood of developing erosive damage early and patients with a less aggressive disease, so as to institute the appropriate therapy at and for the most convenient time. This induced to search for sensitive methods for reliable documentation and precise monitoring of the synovial inflammation process [ 2 – 4 ]. Musculoskeletal ultrasound (MSUS) demonstrated to be a valid and reliable tool in the assessment of chronic inflammatory arthropathies in adults [ 5 – 7 ].…”